The pharmaceutical group Quantum Genomics has announced that Orient EuroPharma has acquired a stake in its capital. Through the signing of this agreement, the two companies are strengthening their long-standing partnership. This investment is perfectly in line with Quantum Genomics' ambitions to better position itself in its sector of activity.
The two groups Quantum Genomics and Orient EuroPharma (OEP) have just consolidated their partnership through the signing of a new agreement. The biopharmaceutical company has announced the acquisition of a stake in the leading pharmaceutical distribution and services company.
In September 2020, Quantum Genomics and OEP announced their intention to sign an exclusive licensing and collaboration agreement. This partnership was aimed at developing and marketing firibastat in Southeast Asia, Australia and New Zealand. Orient EuroPharma's acquisition of a minority stake in the pharmaceutical group's capital is part of the extension of this agreement.
The two companies are thus strengthening their cooperation. For his part, Jean-Philippe Milon, CEO of Quantum Genomics, expressed his company's pleasure at welcoming Orient EuroPharma to its fold. He stated that this acquisition of a stake in the company was a sign of the confidence that the OEP has in him.
The man also did not fail to praise OEP's solid expertise in the pharmaceutical industry.
In his statement, the CEO of Quantum Genomics emphasizes that this new agreement is a great asset that is in line with his company's strategy. The company's strategy is to bring to market a new, unique and globally patented therapeutic class for the treatment of difficult-to-treat/resistant hypertension and heart failure.
Today, Orient EuroPharma reports a subscription to a reserved capital increase, valued at 870 000 euros, i.e. 4.83 euros per share. 4.83 per share. This amount corresponds to the volume-weighted average share price over the last 20 trading days, without discount. Also, a mandatory holding period " lock-up " is associated with the shares issued. Its duration is 3 years.
In addition, a deadline of 25 February 2020 has been set for the settlement-delivery of the new ordinary shares. It is also on this date at the latest that they will be submitted for trading on the Euronext Growth market in Paris. Therefore, the new shares will be subject to the provisions of the Articles of Association. They are also treated in the same way as the old shares.
Based in Paris and New York, Quantum Genomics is a biopharmaceutical group focused on the development of a new class of drugs with a direct effect on the brain to treat resistant hypertension and heart failure. These drugs are based on the mechanism of inhibition of Brain Aminopeptidase A Inhibition (BAPAI).
Quantum Genomics is recognized as the only company worldwide to pursue this innovative approach that targets the brain directly. The company also has a strong presence in the equity markets. On the Paris Stock Exchange, it is listed on the Euronext Growth market. The company is also listed on the American OTCQX market.